SymBio Pharmaceuticals - Treakisym label expansion submitted
SymBio announced on 11 May 2020 that it submitted an application to expand the label for Treakisym in Japan to include the treatment of relapsed...
127 Views
SymBio Pharmaceuticals - Treakisym label expansion submitted
SymBio announced on 11 May 2020 that it submitted an application to expand the label for Treakisym in Japan to include the treatment of relapsed...
126 Views
SymBio Pharmaceuticals - Supply issues continue
SymBio reported sales of $25.8m (¥2.838bn) for 2019 and an operating loss of $39.1 (¥4.301bn). Sales were down from 2018 due to the previously...
675 Views
SymBio Pharmaceuticals - Supply issues continue
SymBio reported sales of ¥2.838bn for 2019 and an operating loss of ¥4.301bn. Sales were down from 2018 due to the previously announced quality...
689 Views
SymBio Pharmaceuticals - Treakisym has positive DLBCL results
On 5 November 2019, SymBio announced it obtained positive results in its pivotal Phase III clinical trial of Treakisym (bendamustine) in patients...
1.7k Views